Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?

Table 6 Univariate analysis of prognostic factors to grade 2 or higher acute and late gastro-intestinal (GI) and genito-urinary (GU) toxicities:

	P values
Variable	acute GI	acute GU	late GI	late GU
Surgical status: operated	0.667	0.009	1.000	0.527
Neo-adjuvant hormonal therapy	0.939	0.115	0.137	0.492
Diabetes mellitus	0.428	0.889	0.317	0.825
Systemic Arterial Hypertension	0.042	0.905	1.000	1.000
Dmean (Gy)	0.176	0.042	0.600	0.042
Dmax (Gy)	0.118	0.215	0.702	0.202
Dmin (Gy)	0.178	0.049	0.205	0.582
D55 (Gy)	0.164	0.885	0.568	0.552
D30 (Gy)	--	0.593	--	0.860
D25 (Gy)	0.889	--	0.426	--
D10 (Gy)	0.352	--	0.321	--
V47 (%)	0.088	0.614	0.583	0.626
V70 (%)	0.731	0.394	0.852	0.696

D55: dose at 55% of the volume (rectum or bladder); D30: dose at 30% of the volume (rectum or bladder); D25: dose at 25% of the volume (rectum or bladder); D10: dose at 10% of the volume (rectum or bladder); Dmean: mean dose to PTV; Dmax: maximum dose to PTV; Dmin: minimum dose to PTV; V47: volume receiving 47 Gy (rectum or bladder); V70: volume receiving 70 Gy (rectum or bladder)

ISSN: 1748-717X